Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 janv. 2026 07h00 HE | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Autolus announced preliminary unaudited net product revenue from sales of AUCATZYL® (obe-cel) for the fourth quarter and full year of 2025.
08 déc. 2025 08h35 HE | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients was presented at ASH 2025.
19 sept. 2024 07h00 HE | Source: Autolus Therapeutics plc

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer